Sagimet, NASH liver disease drug developer, sets terms for $75M IPO (Pending:SGMT)
Chunumunu Sagimet Biosciences (SGMT), which has been growing therapies for liver illnesses reminiscent of NASH, has ...
Read moreCATEGORIES
BROWSE BY TAG
Bank
Biggest
Bitcoin
Business
buy
Capital
Crypto
Data
Day
Deal
Dividend
Earnings
Episode
Estate
Faber
financial
growth
Guide
high
Investing.com
Investment
Investors
List
making
Market
Meb
million
Money
moves
personalfinance
Platform
Price
Rate
Real
Report
Research
Reuters
Review
Stock
Stocks
Top
Trading
U.S
Watch
week
Copyright © 2023 Special Business Center.
Special Business Center is not responsible for the content of external sites.